Eli Lilly and Company’s LLY shares have risen 4.3% since it reported fourth-quarter results on Feb. 6. Lilly’s fourth-quarter ...

Expected out-of-pocket costs for commonly prescribed brand name medications have grown substantially for Medicare Part D beneficiaries as drug plans increasingly tie patient costs to list prices, ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

Expected out of-pocket costs for commonly prescribed brand name medications have grown substantially for Medicare Part D ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Eli Lilly and Company ...

supporting products like GLP-1 agonist Trulicity (dulaglutide) and dual GIP/GLP-1 agonist Mounjaro (tirzepatide) for diabetes, as well as newly-approved obesity therapy Zepbound (tirzepatide).

Also in the portfolio is another diabetes drug, Forxiga ... Harvard Pilgrim agreed similar deals with Lilly for its GLP-1 drug Trulicity and Novartis’ heart failure drug Entresto.

Trulicity (dulaglutide) is a prescription drug that can cause weight loss in some people but is not approved for this use.

Feb. 12, 2025 — People with type 1 diabetes require continuous insulin treatment and must regularly measure their glucose levels. With open-loop therapies, insulin administration is manually ...

Intermittent fasting may benefit people with type 2 diabetes. Many people believe that intermittent fasting can aid weight loss and offer other health benefits. This article examines whether this ...

The cost of Rybelsus can vary based on several factors, including your insurance coverage. Coupons and drug savings programs can also lower the price you’ll pay for Rybelsus. As with all ...